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Abstract 
Background: The clinical signs of active trachoma are often present in the absence of ocular Chlamydia trachomatis 
infection, particularly following mass drug administration. Treatment decisions following impact surveys and in post-
control surveillance for communities are currently based on the prevalence of clinical signs, which may result in fur-
ther unnecessary distribution of mass antibiotic treatment and the increased spread of macrolide resistance alleles in 
‘off-target’ bacterial species. We therefore developed a simple, fast, low cost diagnostic assay (DjinniChip) for diagnosis 
of ocular C. trachomatis for use by trachoma control programmes.
Methods: The study was conducted in the UK, Germany and Tanzania. For clinical testing in Tanzania, specimens 
from a sample of 350 children between the ages of 7 to 15 years, which were part of a longitudinal cohort that began 
in February 2012 were selected. Two ocular swabs were taken from the right eye. The second swab was collected dry, 
kept cool in the field and archived at – 80 °C before sample lysis for DjinniChip detection and parallel nucleic acid 
purification and detection/quantification by qPCR assay.
Results: DjinniChip was able to reliably detect > 10 copies of C. trachomatis per test and correctly identified 7/10 
Quality Control for Molecular Diagnostics C. trachomatis panel samples, failing to detect 3 positive samples with 
genome equivalent amounts ≤ 10 copies. DjinniChip performed well across a range of typical trachoma field condi-
tions and when used by lay personnel using a series of mock samples. In the laboratory in Tanzania, using clinical sam-
ples the sensitivity and specificity of DjinniChip for C. trachomatis was 66% (95% CI 51–78) and 94.8 (95% CI 91–97%) 
with an overall accuracy of 90.1 (95% CI 86.4–93).
Conclusions: DjinniChip performance is extremely promising, particularly its ability to detect low concentrations of 
C. trachomatis and its usability in field conditions. The DjinniChip requires further development to reduce inhibition 
and advance toward a closed system. DjinniChip results did not vary between local laboratory results and typical 
trachoma field settings, illustrating its potential for use in low-resource areas to prevent unnecessary rounds of MDA 
and to monitor for C. trachomatis recrudescence. 
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Background
Globally, approximately 40 million people, mostly chil-
dren, are thought to have active trachoma at any given 
time [1]. The World Health Organization (WHO) rec-
ommends community-based mass drug administration 
(MDA) coupled with facial hygiene and environmental 
improvements (key components of the SAFE strategy 
(Surgery for trichiasis, Antibiotics, Facial cleanliness, 
Environmental improvements)) in districts where the 
prevalence of the clinical sign of trachomatous inflam-
mation-follicular (TF) is ≥ 10% among children aged 
1–9  years. However, a critical issue for control pro-
grammes is the poor correlation between disease signs 
and infection particularly after MDA; the long-term per-
sistence of clinical signs leads to uncertainty about the 
impact of programmes [2].
Currently, ocular infection testing is not recommended 
by the WHO as an indicator for national trachoma pro-
grammes. There is continued need for low-cost, simple 
to use tests for Chlamydia trachomatis to guide district-
level treatment decisions, particularly around whether 
MDA can be discontinued, and to support the WHO-led 
process to validate elimination as a public health prob-
lem in formerly endemic regions. In order to be suitably 
sensitive and specific, the diagnostic test should detect 
C. trachomatis nucleic acid, require minimal sample 
preparation and testing should be performed at a district-
level laboratory [3, 4]. Several nucleic acid amplification 
(NAAT) tests are available which have excellent sensi-
tivity and specificity (> 95%) for chlamydial infections, 
including the Cepheid Xpert CT/NG test (result in 90 
min) and the Atlas Genetics  io® CT/NG test (result in 
30  min) which require minimal sample preparation [5, 
6]. Both however require specialised proprietary instru-
ments and a robust alternating-current electric power 
supply form a national utility grid or local generator. 
Each are cost-prohibitive (> US$10/test) and the through-
put for programmatic use may be insufficient.
A novel isothermal NAAT diagnostic device for C. 
trachomatis detection was developed; “DjinniChip”, 
intended to be utilised by trachoma surveillance and con-
trol programmes. The test was designed to be performed 
primarily at the district level laboratory by lay personnel 
and requires only a portable heat block, able to be pow-
ered by 12V car battery, with a total test time of approxi-
mately 50 min. The approximate cost per test after 
scale-up is < US$2; however, the test is not yet available 
commercially and its performance has not been formally 
evaluated. The aim of this study was to perform a pre-
liminary evaluation of the performance of the DjinniChip 
from archived ocular clinical samples in a trachoma-
endemic region in-country, initially in the controlled 
environment of a research laboratory. The secondary aim 
was to determine the DjinniChip’s resilience and usability 
when used in typical conditions and facilities where tra-
choma is endemic and by lay personnel.
Methods
Study design, participants and sample size
A retrospective study was conducted using archived 
conjunctival swab samples collected from children in 
trachoma-endemic communities in northern Tanzania 
to assess the performance of the DjinniChip. In February 
2012, we recruited a cohort of children from three adja-
cent trachoma endemic villages in Kilimanjaro and Aru-
sha regions, northern Tanzania. All children, between the 
ages 3 and 11 years, who were normally resident in one 
of the three villages, were eligible for inclusion (n = 666) 
[7]. A total of 616 children were enrolled and the cohort 
was initially followed-up every 3 months for 4 years, for a 
total of 17 time-points. Two conjunctival swab samples 
were collected consecutively from the right eye at each 
time-point. Time-point 14 (August 2015) was selected 
for this evaluation and 428 children were seen, 9 months 
after the last mass community treatment with antibiotic 
as detailed by the SAFE strategy. Conjunctival swabs were 
collected as previously described using sterile polyester-
tipped swabs [7, 8]. The first swab was collected into 
250  µl RNA later and was used elsewhere [7–9], whilst 
the second swab was collected dry and stored at − 80 °C 
until used in this study. 0.5% of swabs collected were ‘air’ 
control swabs in order to test for field- and laboratory 
contamination. These samples were collected by passing 
a swab 10 cm from a participantʼs everted eye, these were 
labelled and processed identically to participant samples.
The study sample size was determined by the number 
of DjinniChips manufactured and shipped to KCRI-BL 
(Tanzania) for the study (n = 600) and the number of par-
ticipants seen at time-point 14 (n = 428). Based on the 
observed infection prevalence 9 months after MDA treat-
ment round 1 (time-point 7) and 2 (time-point 11) the 
expected prevalence of ocular infection was estimated 
at 8%. The precision of the prevalence estimate based on 
this sample size at the 95% confidence level is 5%. Alter-
natively, assuming the index test (DjinniChip) achieves 
sensitivity and specificity of 95%, a sample size of 428 
would achieve an odds of diagnosing a true (qPCR) posi-
tive of 62% (95% CI 51–72%) and an odds of 1% (95% CI 
0–2%) of a false negative.
The WHO endorsed SAFE strategy (surgery for trichia-
sis (in-turned eyelashes), antibiotics, facial cleanliness, 
and environmental improvement) was implemented in 
the study villages as approved by the Tanzanian Minis-
try of Health (MoH). Education about environmental 
improvements and facial hygiene was provided by the 
field team, free trichiasis surgery was offered, and all 
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members of the three villages (including study partici-
pants) were offered azithromycin for trachoma control 
immediately following time-points 3, 7 and 11 specimen 
collection in August of the years 2012, 2013, and 2014.
DNA extraction
Dry clinical samples were thawed and 400  µl of 
lysis-amplification buffer (20  mM Tris-HCl, 10  mM 
 (NH4)2SO4, 150  mM KCl, 2  mM  MgSO4, 0.1%  Tween® 
20, 1% Triton X, pH 8.8) was added to the tube. Samples 
were vortexed for 30 s, pulse-centrifuged, and incubated 
for 10  min at 95  °C for sample lysis. Lysates were then 
pulse-centrifuged and incubated at room temperature 
for 10 min. For the positive control (PC), 46 µl of lysis-
amplification buffer was spiked with 4 µl C. trachomatis 
DNA (10,000 omcB copies/µl) derived from C. trachoma-
tis L2/434 which was originally cultured and prepared 
at the London School of Hygiene & Tropical Medicine 
(LSHTM). For the negative control (NC), 50 µl of lysis-
amplification buffer was used. One hundred microliters 
of sample lysate was used for DNA extraction and C. tra-
chomatis detection by quantitative PCR (qPCR) and 25 µl 
was used for C. trachomatis detection by DjinniChip (see 
below). Remaining sample lysate was stored at − 20 °C.
qPCR detection of C. trachomatis
One hundred microliters of sample lysate was mixed 1:1 
with 100 µl of sterile PBS and DNA was extracted using 
the QIAamp DNA mini kit (Qiagen Ltd, Manchester, 
UK) following the manufacturer’s instructions. DNA was 
eluted into 60  µl of buffer AE and stored at 4  °C prior 
to qPCR testing. Chlamydia trachomatis was detected 
using a reference qPCR assay, which has previously been 
evaluated against droplet digital PCR and Artus (Qiagen 
Ltd, Manchester, UK) C. trachomatis diagnostic assays 
for ocular samples [10]. The triplex qPCR assay detects 
chlamydial chromosomal (omcB) and plasmid (pORF2) 
targets and a human endogenous control gene (RPP30). 
Samples were tested in duplicate, with each 20 µl reaction 
containing 1× TaqMan Multiplex Master Mix (Thermo 
Fisher Scientific, Inchinnan, UK), 300 nM of all prim-
ers and probes and 4 µl DNA. Samples were considered 
C. trachomatis positive if RPP30 in combination with 
pORF2 and/or omcB targets amplified in < 40 cycles in 
either or both replicates. qPCR data were processed in 
STATA v15 and target concentrations were calculated 
by extrapolating from a standard curve. Clinical informa-
tion from participants at time-point 14 was available to 
the assessors of the reference qPCR test but the result of 
the index test was masked until the laboratory study was 
completed.
Droplet digital PCR (ddPCR) detection of C. trachomatis
ddPCR was used to detect and quantify C. trachomatis 
infectious load in 12 archived conjunctival clinical sam-
ples and in Quality Control for Molecular Diagnostics 
(QCMD, Glasgow, UK) panel samples for the prelimi-
nary evaluation of DjinniChips. Dry, frozen conjunc-
tival swabs from 4 C. trachomatis-negative and 8 C. 
trachomatis-positive individuals, previously determined 
by an in-house 16S rRNA qPCR [11], were incubated 
for 10 min at room temperature in 400 µl elution buffer 
(1× PBS or 1% Triton X-100 + 10 mM Tris-HCl (pH7)). 
200  µl of eluate was frozen for DjinniChip evaluation. 
DNA was extracted from the remaining 200 µl using the 
Blood and Serum DNA Isolation Kit (BioChain Insti-
tute Inc, Newark, CA, USA). For QCMD samples, DNA 
was extracted using the QIAamp Mini DNA Extraction 
(Qiagen Ltd, Manchester, UK). Chlamydia trachoma-
tis plasmid and genome were quantified as previously 
described [10].
Preparation of DjinniChips
DjinniChip is an integrated diagnostic platform 
which amplifies DNA from the chromosomal porB 
gene of C. trachomatis using loop-mediated isother-
mal amplification (LAMP). The chips were produced 
by injection-moulding of cyclic olefin copolymer in 
Kunststoff-Zentrum in Leipzig (Germany). The rea-
gents for LAMP were freeze-dried in the channel of the 
chip. Each portion of reaction mix contained 300 nmol 
 MgSO4 , 16  U glycerol-free Bst 3.0 polymerase (New 
England Biolabs (Frankfurt am Main, Germany), 
25  mmol of dA, dG, dC, 22.5  mmol of dU, 0.5  mmol 
dT (Jena Bioscience, Jena, Germany), 10 pmol of prim-
ers B3 and F3, 80 pmol of primer BIP, 60 pmol of unla-
belled primer FIP, 20  pmol of 5’-biotin-labelled FIP, 
40  pmol of 5’-FAM-labelled primer LB and 40  pmol 
of 5’-biotin-labelled primer LF (Eurofins Genomics, 
Ebersberg, Germany), 0.25  mg/ml (w/v) BSA and 6% 
trehalose (Sigma Aldrich, Taufkirchen, Germany). The 
primer sequences are provided in Table 1. The freeze-
dried reagents were overlaid with a 4.3 × 35  mm PES 
filter membrane (Merck Millipore, Darmstadt, Ger-
many), 0.22  µm pore size. A lateral flow test strip 
DetectLine Basic (Amodia, Braunschweig, Germany) 
was placed in the chip, and the bottom surface of the 
chip was sealed with  Masterclear® real-time PCR Film 
(Eppendorf, Hamburg, Germany). DjinniChips were 
manufactured < 6  weeks prior to testing and were 
stored in vacuum-sealed sachets at 4  °C until use. The 
quality of each batch of the chips was verified by testing 
a positive (0.001 ng C. trachomatis DNA) and a nega-
tive control on random chips from the batch.
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DjinniChip detection of C. trachomatis
Twenty-five microliters of sample lysate (see “DNA 
extraction” section above) was mixed with 25  µl lysis-
amplification buffer and the entire 50 µl was added to the 
DjinniChip. Sample extract was driven by capillary effect 
into the reaction channel, dissolving the lyophilized rea-
gents. The inlets of the chip were sealed with Air-O-Seal 
membrane (4titude, Berlin, Germany). Following incuba-
tion on the flat bed of a heat block for 35 min at 65  °C 
for the LAMP reaction, the reaction was stopped by plac-
ing the DjinniChip on a flat ice block (cooling battery) 
for 2–5  min. The amplified product was then manually 
pumped towards the integrated lateral flow strip (LFS) 
by injecting 180  µl chromatographic buffer (Amodia, 
Braunschweig, Germany) into the sample inlet. Biotin- 
and fluorescein (FAM)-labelled amplicons allowed LFS 
detection after 10 min incubation at room temperature, 
by use of gold nanoparticles attached to anti-fluorescein-
antibodies (Fig. 1). A positive control signal (C) and sig-
nal at the test zone (T) corresponded to C. trachomatis in 
the patient sample. Results were recorded electronically, 
and photographic records were taken of each test result.
Samples were analysed using a second DjinniChip if 
(i) the negative no-template control (NC) was weakly or 
strongly positive for the analysed batch of samples, or 
(ii) if the test band was only weakly positive (Additional 
file  1: Figure S1). In either of these cases positive sam-
ples were re-tested, with additional positive and negative 
controls. The outcome of the second test was used as the 
final result: if the NC was negative but the sample was 
weakly positive again, the sample was determined posi-
tive. Clinical information and the reference test results 
were masked to the assessors of the Djinnichip results. 
The study was conducted and reported according to the 
STARD guidelines for diagnostic studies (Additional 
file 1: Table S1) [12].
Mock samples
In order to determine the resilience and usability of 
the DjinniChip, 100 mock samples were tested in field 
conditions. Mock samples consisted of a 50 µl suspen-
sion of C. trachomatis A2497 elementary bodies at four 
different concentrations (below) in PBS which were 
added to sterile polyester-tipped swabs and stored dry 
in 1.5  ml tubes at − 80  °C for a minimum of 1  week. 
Chlamydia trachomatis A2497 was grown in HEp-2 
cells and purified as previously described and quanti-
fied by ddPCR [13]. Four field sites were selected: two 
humid and warm and two hot, dry and dusty. Results 
were compared to replicate mock samples tested on 
DjinniChips at Kilimanjaro Clinical Research Institute-
Biotechnology Laboratory (KCRI-BL). At each of the 
five sites, 20 mock samples ranging in C. trachomatis 
concentration were tested (quadruplicates of nega-
tive control, 160 copies/swab, 800  copies/swab, 3200 
copies/swab, 16,000  copies/swab); 10 duplicates by an 
experienced laboratory technician and 10 duplicates by 
a field nurse who received basic training. A heat block 
(Thermo Fisher Scientific, Inchinnan, UK) powered 
from a 12V direct-current car battery was used to heat 
samples at mobile field sites. DjinniChip testing was 
performed in the open boot of a stationary Land Rover. 
The field team drove to each field site (selected to pro-
vide a range of typical trachoma environmental condi-
tions), where testing was performed in the open boot 
of the stationary vehicle. Samples were transported on 
ice in a cool box and reactions were stopped on the sur-
face of flat ice blocks. Results (including photograph), 
temperature, humidity and time to process 10 tests 
was recorded. Remaining sample extract was frozen at 
− 20  °C prior to DNA extraction (Qiagen Ltd, Man-
chester, UK) and qPCR testing for C. trachomatis.
Results
Preliminary evaluation
DjinniChip performance was initially tested in a Euro-
pean research and development laboratory (Fraun-
hofer IZI, Leipzig) using anonymised conjunctival dry 
swab samples that had been collected and stored in an 
identical manner from a previous study [14] to that 
described for time-point 14 in parallel with a QCMD 
panel. Of the 12 clinical swabs tested, the DjinniChip 
correctly diagnosed all samples as C. trachomatis 
positive or negative; 8/8 positives and 4/4 negatives 
(Table  2, Additional file  1: Figure S2). The concentra-
tion of the sample with the lowest chlamydial load, 
correctly identified as positive by the DjinniChip, was 
36 genome copies per reaction (corresponding to 573 
copies per swab; quantified by ddPCR). The QCMD 
panel consisted of the extracted DNA of urogenital C. 
trachomatis serovars from swabs and urine. Of the 10 
QCMD samples tested, 2/2 negatives and 5/8 positives 
Table 1 LAMP primers for the detection of Chlamydia 
trachomatis by DjinniChip
Primer Sequence (5’–3’)
F3 CTC TGC TTC TGC GGA GAT 
B3 CAG CGA ACG ATC AGG AAG 
FIP AGG AGA AGG ACC AAC CCC AGC TCA GGT AAA AGA TGT CCCT 
BIP TTC GAC AAC CAA AAC GCG AAG GAA AAA GCT ACA GCT ACAC 
LF CTG TTG TCA CAG AGG TAA CGAC 
LB CGA TCT CGT GAA CTG TAA TCT CAA T
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were correctly diagnosed by the DjinniChip (Table  3, 
Additional file  1: Figure S3). The three false negatives 
were the three lowest concentration samples, each at 10 
target copies per reaction.
Evaluation with clinical samples
The demographic and clinical characteristics of the 350 
participants retained in the Djinnichip analysis are shown 
in Table 4. In the field, 430 dry swab specimens were col-
lected (428 clinical samples and 2 ‘air controls’ as detailed 
in Methods). Of these, 352 dry swab samples were eluted 
and tested in parallel using the DjinniChip and the ref-
erence test (qPCR) at the KCRI-BL research laboratory, 
Moshi, Tanzania (Table  5, Additional file  1: Table  S2). 
Seventy-eight consecutive dry swab samples (CD101-
178) were excluded due to a laboratory error in specimen 
processing (unrelated to DjinniChip testing). There were 
18 DjinniChip false negatives relative to qPCR diagnosis; 
of these, 9 had high chlamydial load by qPCR, with over 
100 copies per µl of extracted DNA (Fig. 2). The perfor-
mance characteristics of sensitivity, specificity, PPV, NPV 
and accuracy for all 352 specimens (350 clinical samples 
and 2 air controls) are shown in Table 6. The Djinnichip 
identified fewer specimens from those with the clinical 
signs of trachoma (21 vs 30) and tended to identify more 
specimens from individuals with normal healthy con-
junctivae without any clinical signs of trachoma (31 vs 
23).
Field evaluation
In order to test the performance and usability of the 
DjinniChip in field conditions, a series of mock swabs 
spiked with C. trachomatis were tested at four field 
sites in northern Tanzania. Replicate mock swabs were 
also tested in the laboratory at KCRI-BL, Tanzania, for 
comparison.
In the laboratory, 8/8 C. trachomatis-positive mock 
swabs, ranging in concentration from 160–16,000 copies 
per swab (equivalent to 10–1000  copies per DjinniChip 
reaction), were correctly diagnosed as positive by the 
DjinniChip and by qPCR (Additional file  1: Table  S2.). 
Duplicate negative control swabs were correctly diag-
nosed as negative by both methods.
In the field, 62/64 C. trachomatis-positive mock sam-
ples were correctly diagnosed as positive by the DjinniChip 
(Additional file  1: Table  S3). There were two false nega-
tives, both with concentrations of 50 copies per DjinniChip 
reaction; one tested by an experienced technician and one 
by a field nurse. In contrast, 10/16 negative control sam-
ples tested in the field were incorrectly diagnosed as C. tra-
chomatis positive by the DjinniChip. Six false positives were 
tested by a field nurse and four by an experienced techni-
cian. qPCR testing confirmed that all 16 controls were C. 
trachomatis negative, suggesting that cross-contamination 
had occurred in the field after the sample lysis step. In the 
field, the time taken to test 10 samples was approximately 
70 min (ranging from 135–150 min for 20 samples).
Fig. 1 Schematic principle of the DjinniChip. a Principle of the detection of LAMP product on LFS. b Components and processes. The DjinniChip 
contains lyophilized reagents (1) and a lateral flow test strip (2). A liquid sample (3) is loaded onto the chip through its inlet. The liquid sample 
reconstitutes the reagents (4). Chlamydia trachomatis DNA is amplified at 65 °C. The reaction mix is pumped gently with a syringe to the lateral flow 
test (5). The appearance of the Control band (C) indicates the correct function of the lateral flow test. The appearance of the Test band (T) indicates 
the presence of C. trachomatis in the sample. c Detection on DjinniChips
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Discussion
We developed and evaluated a LAMP-based first genera-
tion DjinniChip assay using ocular swabs collected in the 
course of a longitudinal trachoma cohort study in Moshi, 
Tanzania. DjinniChips enabled fast, simple process-
ing and molecular diagnosis of C. trachomatis infection 
in resource limited environments typical of trachoma-
endemic regions. The results demonstrated high speci-
ficity of the test (94.3%) but modest sensitivity (66%), 
which requires improvement before the DjinniChip can 
be considered for use in trachoma control programmes.
Sensitivity was affected by both false-positive results 
(17/52 (32.6%)) strongly impacting PPV, and false-negative 
results (18/300 (6%)) impacting NPV. The lower sensitivity 
of Djinnichip also resulted in a lower frequency of detec-
tion of infection in those with clinical signs of active tra-
choma but a higher frequency of infection in those with no 
clinical signs of disease. The results overall are more typi-
cal of an untreated trachoma-endemic population where 
current infection is detected in around 60% of active tra-
choma cases [15]. Indeed, the national trachoma control 
programme delivered a fourth round of community treat-
ment with azithromycin in September 2015 to one of the 
three villages in this study where the prevalence of  TF1–9 
was > 10% as per the WHO recommendation.
The majority of the false-negative results were due to 
inhibition of the reaction, which could be overcome 
by dilution of the sample lysate. The assay design cur-
rently uses 25  µl of sample lysate (combined with 25  µl 
buffer); this large amount of sample lysate may negatively 
affect the performance of the test due to the presence of 
excess proteins (such as DNAses and proteases that are 
incompletely inactivated by heating), blood, inflamma-
tory exudate, and dust. In 10 of 18 false-negative samples 
the inhibition was overcome by repeating the test with a 
1:10 dilution of sample lysate to diluent. This is a well-
described characteristic of NAATs which is overcome 
in the same manner with some commercial tests such as 
Roche CT/NG Amplicor [16]. Alternatively, stabilizing 
additives such as increased concentrations of albumin or 
sheared carrier DNA can be added to the diluent. Further 
sample dilution and the use of additives will be optimised 
in the next iteration of the DjinniChip.
Table 2 Evaluation of DjinniChip in eluted ocular swabs
DjinniChip samples were tested at the Fraunhofer Institute, Germany. ddPCR 
was performed at LSHTM, UK
Key: +, positive; –, negative
C. trachomatis 
genome copies per 
swab
C. trachomatis genome copies per 
reaction on chip (sample of 25 µl)
DjinniChip 
test result
0 0 −
0 0 −
0 0 −
0 0 −
573 36 +
1579 99 +
1794 113 +
6739 421 +
13270 830 +
14989 936 +
185611 11,601 +
627486 39,218 +
Table 3 Evaluation of DjinniChip in QCMD (Quality Control for Molecular Diagnostics) DNA sample panel
DjinniChip samples were tested at the Fraunhofer Institute, Germany
LGV, lymphogranuloma venereum
Key: +, positive; –, negative
a Samples with low copy number identified on DjinniChip as negative
Sample code Sample content Copies/µl of extracted 
DNA
Results of DjinniChip test (sample 
of 10 µl)
Copies/
reaction on 
chip
CTDNA17S-01 C. trachomatis (LGV) 3  + 30
CTDNA17S-02 C. trachomatis (LGV) 1 – a 10
CTDNA17S-03 C. trachomatis (LGV) 11  + 110
CTDNA17S-04 C. trachomatis (LGV) 6  + 60
CTDNA17S-05 C. trachomatis (Genovar F) 5  + 50
CTDNA17S-06 C. trachomatis (LGV) 1 – a 10
CTDNA17S-07 C. trachomatis (LGV) + N. gonorrhoeae 
(ST49226)
1 –a 10
CTDNA17S-08 Negative 0 – 0
CTDNA17S-09 C. trachomatis (Swedish strain) 433  + 4330
CTDNA17S-10 Negative 0 – 0
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The extreme sensitivity of LAMP to contaminat-
ing DNA most likely explains the false positivity rate 
[17–19]. DNA ‘contamination’ may occur either dur-
ing DjinniChip manufacture or more likely during use. 
Standard precautions to avoid DNA contamination dur-
ing manufacture and assembly were taken. The false-
positive results observed were predominantly found in 
cases where the test result was ambiguous, evidenced by 
a faint band on the lateral flow strip. With the exception 
of one sample (with a high copy number), true positive 
samples were characterized by clear distinct bands, even 
when only a low copy number was present. DNA con-
tamination during testing most likely occurred during 
sample lysis and loading, or post-amplification when the 
seal was removed to enable the amplified reaction mix 
to be pumped towards the lateral flow test strip. DNA 
contamination is frequently caused by aerosol and in the 
molecular laboratory this can be more easily controlled 
with aerosol barrier tips and the spatial/physical separa-
tion of the procedures. This is more difficult to control in 
a general laboratory, local health facility and under differ-
ing environmental conditions in the field where a closed 
system would offer a solution.
Although the susceptibility to sample inhibition and 
cross-contamination negatively affected the sensitiv-
ity of the test, other characteristics of the DjinniChip 
favour its use for rapid diagnostics in resource-limited 
settings. Due to the simplicity of the test, the DjinniChip 
can be used in the absence of laboratory infrastructure. 
The isothermal DNA amplification was performed on 
a simple and cheap 12V heating block powered from 
a car battery; its use requires minimal operator train-
ing and needs no software. All reagents are pre-stored 
on the chip and it requires storage at only 2–8  °C. Fur-
thermore, sample preparation is relatively simple, and 
Table 4 Demographic details and the distribution of the severity of clinical signs of trachoma in the study and evaluation sample 
population
FPC-scores: Clinical signs were graded using the 1981 WHO Detailed Trachoma Grading System (FPC). This divides the clinical signs into several four-point (0–3) 
increasing severity scales: follicles (F), papillary inflammation (P), and conjunctival scarring (C). This system corresponds to the WHO Simplified Trachoma Grading 
System in the following way: trachomatous inflammation-follicular (TF) is equivalent to F2/F3 and trachomatous inflammation-intense (TI) is equivalent to P3. 
DjinniChip and qPCR testing was performed at KCRI-BL, Moshi, Tanzania
All (Time-point 14) Retained in test 
evaluation
Reference test DjinniChip test
Ct-negative Ct-positive Ct-negative Ct-positive
N 428 350 297 53 298 52
Median age (range) 10 (7–15) 10 (7–15) 10 (7–14) 9 (7–14) 10 (7–14) 9 (7–14)
Sex: female, n (%) 194 (45.3) 161 (46) 152 (52.9) 32 (60) 157 (52.7) 32 (61.5)
F-score, n (%)
 0 353 (82.5) 283 (80.9) 266 (89.6) 17 (32.1) 257 (86.2) 26 (50.0)
 1 36 (8.4) 29 (8.3) 21 (7.1) 8 (15.1) 22 (7.4) 7 (13.5)
 2 21 (4.9) 20 (5.7) 9 (3.0) 11 (20.7) 12 (4.0) 8 (15.4)
 3 18 (4.2) 18 (5.1) 1 (0.3) 17 (32.1) 7 (2.4) 11 (21.2)
P-score, n (%)
 0 391 (91.3) 317 (90.6) 284 (95.6) 33 (62.2) 277 (93.0) 40 (76.9)
 1 23 (5.4) 20 (5.7) 8 (2.7) 12 (22.6) 14 (4.7) 6 (11.5)
 2 8 (1.9) 7 (2.0) 3 (1.0) 4 (7.6) 3 (1.0) 4 (7.7)
 3 6 (1.4) 6 (1.7) 2 (0.7) 4 (7.6) 4 (1.3) 2 (3.9)
C-score, n (%)
 0 397 (92.8) 328 (93.7) 275 (92.9) 52 (98.1) 278 (93.6) 49 (94.2)
 1 26 (6.0) 19 (5.4) 19 (6.4) 0 17 (5.7) 2 (3.9)
 2 5 (1.2) 3 (0.9) 2 (0.7) 1 (1.9) 2 (0.7) 1 (1.9)
 3 0 0 0 0 0 0
Table 5 Diagnostic performance of the DjinniChip on archived 
clinical samples
DjinniChip and qPCR testing were performed at KCRI-BL, Moshi, Tanzania
a Includes 2 air controls which tested negative by both qPCR and DjinniChip
qPCR-negative qPCR-positive Total
DjinniChip-negative 282a 18 300
DjinniChip-positive 17 35 52
Total 299 53 352
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a test can be completed in 50  min in laboratory condi-
tions, with assessment of test result by visual inspection. 
Other published isothermal assays for C. trachomatis are 
based on conventional laboratory processing and thus far 
have not been translated into suitable formats for use in 
low-resource settings [20–22]. Although there are some 
rapid and point-of-care tests available for C. trachoma-
tis detection, there is currently no integrated molecular 
test developed for trachoma that is characterized by the 
same level of technical simplicity as the DjinniChip. Shin 
et  al. [23] developed a mobile magnetofluidic platform 
for the extraction and amplification of C. trachomatis 
DNA (primarily designed for sexually transmitted infec-
tions); however, their device is reliant on a specialised 
instrument. Most recently, SelfDiagnostics Deutschland 
GmbH (Leipzig, Germany) released a fully integrated 
device for the detection of C. trachomatis and N. gonorre-
hea in urine (STD Multitest); the device is self-contained 
and suitable for home-use; however, its format (internal 
complexity and construction) results in high production 
costs making it suboptimal for neglected tropical disease 
control programmes [24].
The DjinniChip maintained stable performance over 
the entire duration of the study (> 4 weeks including ship-
ping with storage at 4 °C). A preliminary accelerated age-
ing study performed by Fraunhofer IZI (data not shown) 
found that DjinniChip performance remained unaffected 
for at least 10 weeks when stored at ambient temperature 
(~ 23  °C). Field testing in Tanzania revealed that Djin-
niChip detection of C. trachomatis was not impeded by 
temperature ranges between 25–36  °C with humidity 
between 19–50%, even in two field sites with very dusty 
and windy conditions. The main factor affecting Djin-
niChip performance in the field was the high number 
of false positives, probably due to cross-contamination. 
In the field it was not possible to segregate each stage of 
sample preparation, DNA amplification and detection, as 
Fig. 2 Concentration of C. trachomatis positive clinical samples by reference qPCR in target copies per microlitre of extracted DNA, showing those 
diagnosed as positive (blue circles, pos) and negative (red circles, neg) by the DjinniChip
Table 6 Diagnostic performance of the DjinniChip on archived 
clinical samples
DjinniChip and qPCR testing were performed at KCRI-BL, Moshi, Tanzania
DjinniChip vs non-commercial qPCR
Value (%) 95% CI
Sensitivity 66.0 51.7–78.5
Specificity 94.3 91.1–96.7
PPV 67.3 55.5–77.3
NPV 94.0 91.5–95.8
Accuracy 90.1 86.4–93.0
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all processes were conducted in the open boot of a Land 
Rover, and over half of No Template Control samples 
were positive. Work towards the next iteration of Djin-
niChip therefore needs to focus on its translation into a 
fully closed integrated format with no manual handling 
of liquids in order to improve test specificity. DjinniChip 
sensitivity will also be improved by further investigation 
reagent thermostability and storage as well as the modi-
fications that enable sample matrix to prevent inhibi-
tion. Despite the low cost and simple testing procedure 
(particularly in a fully closed integrated format), national 
programmes frequently visit > 1000 individuals during 
surveys and in a low prevalence setting it may be desir-
able to pool samples for infection testing [25]. In the next 
iteration of DjinniChip, the potential to increase sam-
ple throughput by pooling clinical samples needs to be 
assessed.
Conclusions
The DjinniChip rapid molecular diagnostic test for 
C. trachomatis has promising potential; however, it 
requires further development to improve its suitability 
for use by trachoma control programmes. Its strengths 
are the simple operation, fast time-to-result, lack of 
requirements for proprietary or high-cost laboratory 
equipment, and its stability in challenging environmen-
tal conditions. The estimated approximate cost per test 
of < US$2 after scale-up makes it a suitable candidate 
for diagnostic programmes in the future. The current 
limitations of the DjinniChip are its susceptibility to 
DNA contamination due to the manual sample- and 
detection buffer-handling steps and sporadic inhibition 
of the reaction by sample matrix, both of which can be 
eliminated in the next iteration. We were also limited by 
our reduced sample size due to sample loss and higher 
than expected prevalence of ocular infection. For the 
DjinniChip to be useful for trachoma control program-
matic decisions post-MDA only a modest improvement 
in sensitivity may be required to maintain sensitiv-
ity of the test at lower infection prevalence associated 
with elimination targets. Conversely, the higher than 
expected infection prevalence with the reduced sample 
size may have inflated the performance of the index test 
specificity. The test, most likely, currently has sufficient 
high specificity since it would be used to make treat-
ment decisions at the community level. The DjinniChip 
was designed for use by non-specialists in district level 
laboratories or health centres in trachoma endemic 
areas for the surveillance of C. trachomatis. Following 
improvements identified above, the DjinniChip holds 
promising potential to prevent unnecessary rounds of 
MDA and to rapidly detect recrudescence of infection 
in the community.
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